头孢哌酮钠/舒巴坦的两种配方比较鲍曼不动杆菌所致肺部感染的疗效

Clinical Efficacy of Two Proportions of Cefoperazone/sulbactam in the Treatment of Pulmonary Infection with Acinetobacter baumannii

84例肺部感染鲍曼不动杆菌患者随机分为对照组和观察组,各42例,在常规治疗基础上,对照组给予头孢哌酮钠舒巴坦配比为2∶1;观察组给予头孢哌酮钠舒巴坦配比为1∶1;均3 g/次,每8 h静脉滴注1次。治疗14 d后,观察组总有效率和细菌清除率分别为73.81%和78.57%,均大于对照组45.24%和52.38%;观察组CRP和PCT分别为(23.71±10.74)mg·L-1和(0.56±0.28)ng·m L-1均低于对照组(34.78±12.57)mg·L-1和(1.13±0.34)ng·m L-1;观察组体温恢复正常时间、咳嗽咳痰消失时间、机械通气时间和ICU住院时间分别为(6.41±1.82)d、(7.72±2.57)d、(3.89±0.74)d和(8.56±2.33)d,均少于对照组(8.73±2.71)d、(9.85±3.56)d、(5.12±0.87)d和(10.12±3.57)d,差异均有统计学意义(P<0.05);不良反应发生率差异无统计学意义(P>0.05)。结果显示,头孢哌酮钠舒巴坦治疗鲍曼不动杆菌肺部感染的疗效配比1∶1的显著优于2∶1的。

Eighty-four patients with pulmonary infection caused by Acinetobacter baumannii were equally and randomly divided into test group and control group.On the basis of conventional therapy,the control group were given cefoperazone/sulbactam(cefoperazone∶sulbactam=2∶1)and those in the test group were given cefoperazone/sulbactam(cefoperazone sulbactam=1∶1),all at 3 g once every 8 hours in intravenous infusion.After 14 days,the effective rate and bacterial clearance rate of the test group were respectively 73.81%and 78.57%,higher than those of the control group 45.24%and 52.38%;the CRP and PCT of the test group were respectively(23.71±10.74)mg·L-1 and(0.56±0.28)ng·mL-1,lower than those of the control group(34.38±12.57)mg·L-1 and(1.13±0.34)ng·mL-1;the times of body temperature returned to normal,cough and phlegm disappeared,mechanical ventilation and stay in ICU of the test group were respectively(6.41±1.82)days,(7.72±2.57)days,(3.89±0.74)days and(8.56±2.33)days,shorter than those of the control group(8.73±2.71)days,(9.85±3.56)days,(5.12±0.87)days and(10.12±3.57)days.The differences above were all statistically significant(P<0.05).There was no significant difference in ADR between the two groups(P>0.05).The results show that the clinical efficacy of cefoperazone:sulbactam at 1∶1 is significantly better than that at 2∶1 in the treatment of pulmonary infection with A·baumannii.